Komori
Business alliance4563AnGes,Inc.Pharmaceuticals

Acquisition and cancellation of Stock Acquisition Rights (46), redemption of Series 2 Bonds, third-party allotment of Stock Acquisition Rights (47, with revised exercise price, and 48), issuance of Series 2 Bonds with Stock Acquisition Rights, and business alliance agreement with GP Co.

The company will terminate and redeem the Series 46 stock acquisition rights and bond facility for CFE, and issue stock acquisition rights and convertible bonds with stock acquisition rights to a GP fund. At the same time, it will enter into a business alliance agreement with グロースパートナーズ株式会社, under which the company will receive support not only for financing but also for its business platform, capital policy and business development.

Worth reading
64In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
8500.002315
¥ millions (total payment amount, before deducting issuance expenses)
Wording
Avoiding a definitive answer
How definitive the wording is.

Agreements reached under this partnership

Capital and Business Alliance
4563AnGes,Inc.
Alliance partnerName of alliance partner
Capital and personnel relationships

This indicates whether the companies will do more than work together, such as holding each other’s shares or seconding personnel (capital and business alliance).

Shareholding PolicyThe GP fund does not intend to transfer the stock acquisition rights and convertible bonds with stock acquisition rights to a third party within a short period after their allotment. It intends to sell the common shares acquired through the exercise of the stock acquisition rights or conversion of the convertible bonds with stock acquisition rights, taking market conditions and other factors into consideration.
Change in major shareholdersThe major shareholders and their shareholdings after the offering are not shown because the proposed allottees do not intend to hold the securities on a long-term basis.
About the partner
Business DescriptionA business providing hands-on support to portfolio companies in areas including financial strategy, capital policy, M&A, optimization of business portfolios and enhancement of management control systems. The business of the general partner is investment activities and related operations.
LocationRJ3, 2-16-12 Jiyugaoka, Meguro-ku, Tokyo
Impact on Business Performance

The impact on consolidated results for the fiscal year ending December 2026 from payments such as issuance expenses is immaterial. Although the company believes the transaction will contribute to improved results and corporate value over the medium to long term, it is difficult to reasonably calculate the amount of the impact at this time.

Date of board resolution14 August 2026Contract Date14 August 2026 (including the scheduled date)Share Acquisition Date and Payment Date31 August 2026 (payment date)
Agreements reached under this partnership
ItemDetails
Name of alliance partnerName of alliance partner
Alliance partner's business activitiesA business providing hands-on support to portfolio companies in areas including financial strategy, capital policy, M&A, optimization of business portfolios and enhancement of management control systems. The business of the general partner is investment activities and related operations.
Alliance partner's locationRJ3, 2-16-12 Jiyugaoka, Meguro-ku, Tokyo
Type of allianceCapital and Business Alliance
Shareholding PolicyThe GP fund does not intend to transfer the stock acquisition rights and convertible bonds with stock acquisition rights to a third party within a short period after their allotment. It intends to sell the common shares acquired through the exercise of the stock acquisition rights or conversion of the convertible bonds with stock acquisition rights, taking market conditions and other factors into consideration.
Date of board resolution14 August 2026
Contract Date14 August 2026 (including the scheduled date)
Share Acquisition Date and Payment Date31 August 2026 (payment date)
Impact on Business PerformanceThe impact on consolidated results for the fiscal year ending December 2026 from payments such as issuance expenses is immaterial. Although the company believes the transaction will contribute to improved results and corporate value over the medium to long term, it is difficult to reasonably calculate the amount of the impact at this time.
Change in major shareholdersThe major shareholders and their shareholdings after the offering are not shown because the proposed allottees do not intend to hold the securities on a long-term basis.
Items this document does not state (13)
Alliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeDetails of the allianceNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceAlliance start date

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To secure funds required for research and development investment, working capital and the redemption of existing bonds, thereby stabilizing the company's financial base. The company also aims to improve its business platform and corporate value by leveraging the network and expertise of グロースパートナーズ株式会社 and receiving cooperation in areas including business alliances, capital policy and business development.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Acquisition and cancellation of Stock Acquisition Rights (46), redemption of Series 2 Bonds, third-party allotment of Stock Acquisition Rights (47, with revised exercise price, and 48), issuance of Series 2 Bonds with Stock Acquisition Rights, and business alliance agreement with GP Co. | AnGes,Inc. (4563) timely disclosure | Komori